Reduced axonal transport and increased excitotoxic retinal ganglion cell degeneration in mice transgenic for human mutant p301s tau

PLoS ONE

Volumn 7, Issue 4, 2012, Pages

  Bull, Natalie D ^a   Guidi, Alessandra ^a   Goedert, Michel ^c   Martin, Keith R ^a,b   Spillantini, Maria Grazia ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c MRC LABORATORY OF MOLECULAR BIOLOGY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GANGLIOSIDE GM1; PROTEIN TAU P301S; TAU PROTEIN; UNCLASSIFIED DRUG; CHOLERA TOXIN; MAPT PROTEIN, HUMAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL DEGENERATION; CONTROLLED STUDY; CRYOPRESERVATION; EXCITOTOXICITY; GENE MUTATION; HOMOZYGOSITY; IMMUNOHISTOCHEMISTRY; LASER MICROSCOPY; MALE; MISSENSE MUTATION; MOUSE; NERVE FIBER TRANSPORT; NEUROPROTECTION; NONHUMAN; OPTIC NERVE; PROMOTER REGION; PROTEIN AGGREGATION; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RETINA GANGLION CELL; TRANSGENE; ANIMAL; C57BL MOUSE; GENETICS; HUMAN; METABOLISM; MUTATION; PATHOLOGY; PHOSPHORYLATION; RETINA DEGENERATION; TAUOPATHY; TRANSGENIC MOUSE;

MUS; MUS MUSCULUS;

ANIMALS; AXONAL TRANSPORT; CHOLERA TOXIN; HUMANS; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MUTATION; PHOSPHORYLATION; RETINAL DEGENERATION; RETINAL GANGLION CELLS; TAU PROTEINS; TAUOPATHIES;

EID: 84859348885     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0034724     Document Type: Article

References (34)

1. Goedert M, Spillantini MG, (2006) A century of Alzheimer's disease. Science 314: 777-781.
2. Poorkaj P, Bird TD, Wijsman E, Nemens E, Garruto RM, et al. (1998) Tau is a candidate gene for chromosome 17 frontotemporal dementia. Ann Neurol 43: 815-825.
3. Hutton M, Lendon CL, Rizzu P, Baker M, Froelich S, et al. (1998) Association of missense and 5′-splice-site mutations in tau with the inherited FTDP-17. Nature 393: 702-705.
4. Spillantini MG, Murrell JR, Goedert M, Farlow MR, Klug A, et al. (1998) Mutation in the tau gene in familial multiple system tauopathy with presenile dementia. Proc Natl Acad Sci USA 95: 7737-7741.
5. Hasegawa M, Smith MJ, Goedert M, (1998) Tau proteins with FTDP-17 mutations have a reduced ability to promote microtubule assembly. FEBS Lett 384: 25-30.
6. Hong M, Zhukareva V, Vogelsberg-Ragaglia V, Wszolek Z, Reed L, et al. (1998) Mutation-specific functional impairments in distinct tau isoforms of hereditary FTDP-17. Science 282: 1914-1917.
7. Nacharaju P, Lewis J, Easson C, Yen S, Hackett J, et al. (1999) Accelerated filament formation from tau protein with specific FTDP-17 missense mutations. FEBS Lett 447: 195-199.
8. Goedert M, Jakes R, Crowther RA, (1999) Effects of frontotemporal dementia FTDP-17 mutations on heparin-induced assembly of tau filaments. FEBS Lett 450: 306-311.
9. Zhang B, Higuchi M, Yoshiyama Y, Ishihara T, Forman MS, et al. (2004) Retarded axonal transport of R406W mutant tau in transgenic mice with a neurodegenerative tauopathy. J Neurosci 24: 4657-4667.
10. Ittner LM, Fath T, Ke YD, Bi M, van Eersel J, et al. (2008) Parkinsonism and impaired axonal transport in a mouse model of frontotemporal dementia. Proc Natl Acad Sci USA 105: 15997-16002.
11. Magnani E, Fan J, Gasparini L, Golding M, Williams M, et al. (2007) Interaction of tau protein with the synactin complex. EMBO J 26: 4546-4554.
12. Pease ME, McKinnon SJ, Quigley HA, Kerrigan-Baumrind J, Pease ME, (2006) Obstructed axonal transport of BDNF and its receptor TrkB in experimental glaucoma. Invest Ophthalmol Vis Sci 41: 764-774.
13. Ko ML, Hu DN, Ritch R, Sharma SC, Chen CF, (2001) Patterns of retinal ganglion cell survival after brain-derived neurotrophic factor administration in hypertensive eyes of rats. Neurosci Lett 305: 139-142.
14. Martin KR, Quigley HA, Zack DJ, Levkvitch-Verbin H, Kielczewski J, et al. (2003) Gene therapy with brain-derived neurotrophic factor as a protection: Retinal ganglion cells in a rat glaucoma model. Invest Ophthalmol Vis Sci 44: 4357-4365.
15. Martin KR, Quigley HA, Valenta D, Kielczewski J, Pease ME, (2006) Optic nerve dynein motor protein distribution changes with intraocular pressure elevation in a rat model of glaucoma. Exp Eye Res 83: 255-262.
16. Allen B, Ingram E, Takao M, Smith MJ, Jakes R, et al. (2002) Abundant tau filaments and nonapoptotic neurodegeneration in transgenic mice expressing human P301S tau protein. J Neurosci 22: 9340-9351.
17. Gasparini L, Crowther RA, Martin KR, Berg N, Coleman M, et al. (2011) Tau inclusions in retinal ganglion cells of human P301S tau transgenic mice: Effects on axonal viability. Neurobiol Aging 32: 419-433.
18. Delobel P, Lavenir I, Fraser G, Ingram E, Holzer M, et al. (2008) Analysis of tau phosphorylation and truncation in a mouse model of human tauopathy. Am J Pathol 172: 123-131.
19. Velasco A, Fraser G, Delobel P, Ghetti B, Lavenir I, et al. (2008) Detection of filamentous tau inclusions by the fluorescent Congo red derivative FSB [trans,trans)-1-fluoro-2,5-bis(3-hydroxycarbonyl-4-hydroxy)styrylbenzene]. FEBS Lett 582: 901-906.
20. Nakanishi N, Tu S, Shin Y, Cui J, Kurokawa T, et al. (2009) Neuroprotection by the NR3A subunit of the NMDA receptor. J Neurosci 29: 5260-5265.
21. Stamer K, Vogel R, Thies E, Mandelkow E, Mandelkow EM, (2002) Tau blocks traffic of organelles, neurofilaments, and APP vesicles in neurons and enhances oxidative stress. J Cell Biol 156: 1051-1063.
22. Mandell JW, Banker GA, (1996) A spatial gradient of tau protein phosphorylation in nascent axons. J Neurosci 16: 5727-5740.
23. Yuan A, Kumar A, Peterhoff C, Duff K, Nixon RA, (2008) Axonal transport rates in vivo are unaffected by tau deletion or overexpression in mice. J Neurosci 28: 1682-1687.
24. Morfini G, Pigino G, Mizuno N, Kikkawa M, Brady ST, (2007) Tau binding to microtubules does not directly affect microtubule-based vesicle mobility. J Neurosci Res 85: 2620-2630.
25. Utton MA, Connell J, Asuni AA, Slegtenhorst, Hutton M, et al. (2002) The slow axonal transport of the microtubule-associated protein tau and the transport rates of different isoforms and mutants in cultured neurons. J Neurosci 22: 6394-6400.
26. Goedert M, Jakes R, Crowther RA, Six J, Lübke U, et al. (1993) The abnormal phosphorylation of tau protein at Ser-202 in Alzheimer disease recapitulates phosphorylation during development. Proc Natl Acad Sci USA 90: 5066-5070.
27. Arendt T, Stieler J, Strijkstra AM, Hut RA, Rüdiger J, et al. Reversible paired helical filament-like phosphorylation of tau is an adaptive process associated with neuronal plasticity in hibernating animals. J Neurosci 23: 6972-6981.
28. Ishihara T, Hong M, Zhang B, Nakagawa Y, Lee MK, et al. (1999) Age-dependent emergence and progression of a tauopathy in transgenic mice overexpressing the shortest human tau isoform. Neuron 24: 751-762.
29. Spittaels K, Van den Haute C, Van Dorpe J, Bruynseels K, Vandezande K, et al. (1999) Prominent axonopathy in the brain and spinal cord of transgenic mice overexpressing four-repeat human tau protein. Am J Pathol 155: 2153-2165.
30. Probst A, Götz J, Wiederhold KH, Tolnay M, Mistl C, et al. (2000) Axonopathy and amyotrophy in mice transgenic for human four-repeat tau protein. Acta Neuropathol 99: 469-481.
31. LaPointe NE, Morfini G, Pigino G, Gaisina IN, Kozikowski AP, et al. (2009) The amino terminus of tau inhibits kinesin-dependent axonal transport: implications for filament toxicity. J Neurosci Res 87: 440-451.
32. Kanaan NM, Morfini GA, LaPointe NE, Pigino GF, Patterson KR, et al. (2011) Pathogenic forms of tau inhibit kinesin-dependent axonal transport through a mechanism involving activation of axonal phosphotransferases. J Neurosci 31: 9858-9868.
33. Saxena S, Caroni P, (2011) Selective neuronal vulnerability in neurodegenerative diseases: from stressor thresholds to degeneration. Neuron 71: 35-48.
34. Gupta N, Fong J, Ang LC, Yucel YH, (2008) Retinal tau pathology in human glaucomas. Can J Ophtalmol 43: 53-60.